Ligand Pharmaceuticals Incorporated (LGND)
After hours:
| Previous close | 80.83 |
| Open | 81.22 |
| Bid | 83.21 x 100 |
| Ask | 83.72 x 100 |
| Day's range | 80.31 - 84.15 |
| 52-week range | 49.24 - 94.57 |
| Volume | |
| Avg. volume | 167,303 |
| Market cap | 1.502B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 15.63 |
| EPS (TTM) | 5.35 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jul 2010 |
| 1y target est | 116.80 |
ZacksDoes Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.3% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksRecent Price Trend in Ligand (LGND) is Your Friend, Here's Why
Ligand (LGND) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Business WireLigand to Participate in Upcoming Investor Conferences
JUPITER, Fla., May 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:
